Social Anxiety Disorder (Social Phobia)

Clinical picture

• Fear concentrates on being judged anxious, boring, or incompetent; blushing, trembling, sweating, and a shaking voice are the dreaded giveaways.
• Avoidance is often invisible: declining promotions, sitting silent in meetings, texting instead of calling, or arriving late to skip small talk.
• The performance-only subtype is confined to public speaking or performing and leaves everyday conversation and dating largely intact.
• Post-event processing keeps patients replaying interactions for hours or days, cementing a distorted image of how they appeared.
• Alcohol is commonly used as pre-social anxiolysis, a pattern that converts smoothly into an alcohol use disorder over time.
• Children may show tantrums, freezing, clinging, or selective mutism rather than articulating any fear of being evaluated.

Criteria snapshot

• Marked fear or anxiety about one or more social situations involving possible scrutiny, including interaction, being observed, and performing.
• The person fears acting in a way, or showing anxiety symptoms, that will be negatively evaluated, humiliating, or lead to rejection.
• Such situations almost always provoke fear, are avoided or endured with intense distress, and the fear is out of proportion to actual threat.
• Duration is typically six months or more, with clinically significant distress or impairment in social or occupational functioning.
• Specify performance only when fear is restricted to speaking or performing publicly; exclude substance, medical, and other disorder explanations.

Neurobiology

• Amygdala and insula hyperreactivity to critical and even neutral faces, with weak dorsolateral and medial prefrontal down-regulation on fMRI.
• Striatal dopamine D2 receptor and dopamine transporter abnormalities distinguish social anxiety from other anxiety disorders in PET studies.
• Serotonin synthesis is elevated in amygdala and raphe regions, a counterintuitive direction that nonetheless accompanies robust SSRI response.
• Heritability approximates 30-40%, and behaviorally inhibited temperament in toddlerhood is the strongest prospective risk marker.
• Exaggerated sympathetic output, including blush reactivity and beta-adrenergically mediated tremor, drives the performance subtype.
• Oxytocin signaling and receptor gene variants modulate social threat appraisal, an active but not yet clinically actionable target.

Psychology

• Clark and Wells model: attention shifts inward to a distorted self-image built from felt anxiety rather than from actual external feedback.
• Safety behaviors such as scripting sentences, avoiding eye contact, or gripping a cup prevent disconfirmation and read as aloofness to others.
• Anticipatory rumination beforehand and post-event processing afterward convert ambiguous encounters into remembered social failures.
• High self-imposed standards for social performance combined with low social self-efficacy generate probability and cost overestimation.
• Peer victimization, shame-focused or critical parenting, and overcontrol interact with inhibited temperament to consolidate the disorder.

Differential & comorbidity

• Differentiate from avoidant personality disorder (pervasive inadequacy across contexts), autism (social communication deficit), and panic disorder.
• Body dysmorphic disorder centers on perceived appearance flaws, while agoraphobia avoidance concerns escape difficulty rather than evaluation.
• Normal shyness lacks the impairment threshold; a direct question about functional cost separates temperament from diagnosable disorder.
• Alcohol use disorder, major depression, and other anxiety disorders are the top comorbidities, with social anxiety usually the primary condition.
• Untreated social anxiety predicts later depression and suicidal ideation, and educational and occupational attainment suffer measurably.

Pharmacologic treatment

• Paroxetine 20-60 mg/day, sertraline 50-200 mg/day, and escitalopram 10-20 mg/day carry the strongest SSRI evidence in this disorder.
• Venlafaxine XR 75-225 mg/day is an equally first-line SNRI option; allow 8-12 weeks at target dose before declaring nonresponse.
• Propranolol 10-40 mg taken 30-60 minutes before a performance blunts tremor and palpitations in the performance-only subtype.
• Benzodiazepines are second-line and problematic given the high rate of comorbid alcohol use disorder in this patient population.
• Gabapentin and pregabalin have modest trial support, and the MAOI phenelzine remains highly effective but is reserved for refractory cases.

Psychotherapy

• CBT with in-session and in-vivo exposure plus deliberate dropping of safety behaviors over 12-16 sessions outperforms medication at follow-up.
• Clark and Wells cognitive therapy, using video feedback and attention training, produces the largest effect sizes reported in the literature.
• Group CBT provides a built-in audience but is not superior to individual therapy; individual format is preferred when severity is high.
• Social skills training helps only where a genuine skills deficit exists; most patients possess the skills but have them inhibited by anxiety.
• Combining CBT with an SSRI adds modest benefit over either treatment alone in severe or heavily comorbid presentations.

Adjunct options

• Track outcome with the Liebowitz Social Anxiety Scale or the Social Phobia Inventory at intake and every four to six weeks thereafter.
• Video feedback corrects the distorted self-image faster than verbal disputation; have the patient predict what they will see before viewing.
• School and workplace accommodations should support graded exposure rather than permit avoidance of presentations, which entrenches impairment.
• Address alcohol use directly, since pre-social drinking is negatively reinforced and systematically undermines exposure-based learning.
• Internet-delivered guided CBT matches face-to-face outcomes and suits patients who cannot tolerate a clinic waiting room.

Clinical pearls

• The fear is of visible anxiety itself; ask what others would conclude if they saw you blush.
• Dropping safety behaviors during exposure predicts outcome more than exposure duration does.
• Onset after age 25 is unusual; look for depression, substance use, or a medical cause instead.